Research programme: enterotoxigenic Escherichia coli vaccine - Sanofi Pasteur/US Naval Medical Research Center
Alternative Names: Travelers diarrhea vaccine - Sanofi/NMRC; Travellers diarrhoea vaccine - Sanofi/US NMRCLatest Information Update: 08 Apr 2022
At a glance
- Originator Naval Medical Research Center; sanofi pasteur
- Developer Naval Medical Research Center; Sanofi
- Class Bacterial vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Traveller's diarrhoea
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Traveller's-diarrhoea in USA
- 12 Apr 2010 Sanofi Pasteur establishes CRADA with the US Naval Medical Research Center for the development of an enterotoxigenic Escherichia coli vaccine
- 12 Apr 2010 Preclinical trials in Traveller's diarrhoea in USA (unspecified route)